Report 1 : TESTING FOR CARCINOGENICITY OF PHARMACEUTICALS : S1, A ; Conditions which require carcinogenicity studies for pharmaceuticals S1, B ; Use of two rodent species S1, C ; Dose selection for carcinogenicity studies of pharmaceuticals (<Session 4>CA
スポンサーリンク
概要
- 論文の詳細を見る
- 日本トキシコロジー学会の論文
- 1996-12-20
著者
-
Usui Toshimi
Central Institute for Experimental Animals
-
Usui Toshimi
Research And Development Division Janssen-kyowa Co.ltd.
-
Usui Toshimi
Research And Development Division Janssen-kyowa Co. Ltd.
-
MASUDA Hiroshi
Research Institute, Sankyo Co. Ltd.
-
Masuda Hiroshi
Research Institute Sankyo Co. Ltd.
関連論文
- Carcinogenic comparative study on rasH2 mice produced by two breeding facilities
- EXAMINATION OF PERCUTANEOUS APPLICATION IN A 26-WEEK CARCINOGENICITY TEST IN CB6F1-TG rasH2 MICE
- Induction of Drug Metabolism-Related Enzymes by Methylcholanthrene and Phenobarbital in Transgenic Mice Carrying Human Prototype c-Ha-ras Gene and Their Wild Type Littermates
- Use of IC tags in short-term carcinogenicity studies on CB6F1-TgrasH2 mice(Carcinogenicity, Proceedings of the 32nd Annual Meeting)
- P8-31 Effect of vehicles for a dermal carcinogenicity testing of CB6F1-TgrasH2 mice(STATISTICAL AND TEST METHODS/LOCAL STIMURATION)(GENERAL SESSION BY POSTER PRESENTATION)(Proceedings of the 31st Annual Meeting)
- P6-41 Comparative study on the carcinogenicity of phenolphthalein in rasH2 and p53 knockout mice(DRUG METABOLISM/CARCINOGENICITY)(GENERAL SESSION BY POSTER PRESENTATION)(Proceedings of the 31st Annual Meeting)
- Influence of the administration route and the vehicle on CB6F1-TgrasH2 mice (CARCINOGENICITY) (GENERAL SESSION BY POSTER PRESENTATION) (Proceedings of the 30th Annual Meeting)
- Background data of human prototype c-Ha-ras transgenic (CB6Fl-TgrasH2) mice (CARCINOGENICITY) (GENERAL SESSION BY POSTER PRESENTATION) (Proceedings of the 30th Annual Meeting)
- Biological characteristics of gene-manipulated mice for carcinogenicity test (CARCINOGENICITY) (GENERAL SESSION BY POSTER PRESENTATION) (Proceedings of the 30th Annual Meeting)
- USE OF IC TAGS IN SHORT-TERM CARCINOGENICITY STUDY ON CB6F1 TGrasH2 MICE
- P-44 Some Consideration to the Significance of Serum Immunogiobulin Levels in the Immunotoxicy Testing(Proceedings of the 27th Annual Meeting)
- 22C-10-5 Differences in toxic changes between CB6F1-Tg-rasH2 mice and their nontransgenic littermates given cyclophosphamide by gavage weekly for 5 or 26 weeks (2) Immunotoxicity.
- 21D-03-1 Differences in toxic changes between CB6F1-Tg-rasH2 mice and their nontransgenic littermates given cyclophosphamide by gavage weekly for 5 or 26 weeks (1) General toxicity.
- P-46 Differences in immunotoxic changes between CB6F1-Tg-rasH2 mice and their nontransgenic littermates given cyclophosphamide by gavage weekly for 5 weeks.(Proceedings of the 27th Annual Meeting)
- Report 1 : TESTING FOR CARCINOGENICITY OF PHARMACEUTICALS : S1, A ; Conditions which require carcinogenicity studies for pharmaceuticals S1, B ; Use of two rodent species S1, C ; Dose selection for carcinogenicity studies of pharmaceuticals (CA
- Design and Evaluation of Rodent Carcinogenicity Studies(Bioassay)
- INTRODUCTORY REMARKS (CARCINOGENlClTY STUDIES)
- TESTING HUMAN PHARMACEUTICALS FOR CARCINOGENIC POTENTIAL : NEW APPROACH IN ICH PROCESS
- Carcinogenic comparative study on rasH2 mice produced by two breeding facilities